Alpha Tau wins FDA clearance to complete enrollment in recurrent glioblastoma REGAIN trial

• Alpha Tau won FDA clearance to complete enrollment in its REGAIN U.S. recurrent glioblastoma trial, resuming recruitment for the final seven patients.
• FDA review of an interim safety report from the first three patients supported continuation; interim data showed 100% local disease control.
• The FDA also authorized two additional U.S. academic cancer centers to join the trial, expanding site access.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606110830PRIMZONEFULLFEED9745477) on June 11, 2026, and is solely responsible for the information contained therein.